why did fda stop tirzepatide Zepbound copycats remain online despite ban FDA ban on compounded tirzepatide:

Safety Considerations and Limitations While research on anti-inflammatory effects appears promising, its important to acknowledge limitations in current knowledge

We observed a clear dose-response relationship in our analysis, with the risk of nAMD increasing as the duration of GLP-1 receptor agonist exposure increased, Muni explained

Adding it to existing insulin therapy or impaired glucose handling can produce unpredictable, severe hypoglycemia

One reason GLP-1s are now discussed in heart-health conversations is the FDAs approval of Wegovy for reducing the risk of major adverse cardiovascular events in certain adults